TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS

被引：0

作者：

Harrison, Stephen A. ^{[1
]}

Abdelmalek, Manal F. ^{[2
]}

Neff, Guy W. ^{[3
]}

Gunn, Nadege ^{[1
]}

Guy, Cynthia D. ^{[2
]}

Alkhouri, Naim ^{[4
]}

Bashir, Mustafa ^{[2
]}

Freilich, Bradley ^{[5
]}

Almeda, Jose ^{[6
]}

Knapple, Whitfield ^{[7
]}

Kohli, Anita ^{[4
]}

Khazanchi, Arun ^{[8
]}

Sheikh, Muhammad Y. ^{[9
]}

Leibowitz, Mark ^{[10
]}

Hogan, Reed ^{[11
]}

White, Judith ^{[12
]}

Kayali, Zeid ^{[13
]}

Rinella, Mary E. ^{[14
]}

Siddiqui, Mohammad S. ^{[15
]}

Kipnes, Mark ^{[16
]}

Moussa, Sam E. ^{[17
]}

Ortiz-Lasanta, Grisell ^{[18
]}

Poulos, John ^{[19
]}

Younes, Ziad ^{[20
]}

Bansal, Meena B. ^{[21
]}

Baum, Seth J. ^{[22
]}

Borg, Brian ^{[23
]}

Ruane, Peter J. ^{[24
]}

White, Alexander ^{[25
]}

Merkes, Kevin ^{[26
]}

Rashmee, Patil ^{[27
]}

Thuluvath, Paul J. ^{[28
,29
]}

Gottwald, Mildred ^{[30
]}

Khan, Mujib ^{[30
]}

Chen, Charles ^{[30
]}

Yan, Andrew Z. ^{[30
]}

Melchor-Khan, Liza ^{[30
]}

Chang, William ^{[30
]}

DePaoli, Alex ^{[30
]}

Ling, Lei ^{[30
]}

Lieu, Hsiao ^{[30
]}

机构：

[1] Pinnacle Clin Res, San Antonio, TX USA

[2] Duke Univ, Durham, NC USA

[3] Covenant Res & Clin, LLC, Sarasota, FL USA

[4] Arizona Liver Hlth, Chandler, AZ USA

[5] Kansas City Res Inst, Kansas City, MO USA

[6] Doctors Hosp Renaissance, Edinburg, TX USA

[7] Arkansas Gastroenterol, Hot Springs, AR USA

[8] Florida Res Inst, Bradenton, FL USA

[9] Fresno Clin Res Ctr, Fresno, CA USA

[10] Natl Res Inst, Delhi, NY USA

[11] GI Assoc & Endoscopy Ctr, Wausau, WI USA

[12] Bioclin Res, Princeton, NJ USA

[13] Inland Empire Liver Fdn, Rialto, CA USA

[14] Northwestern Univ, Evanston, IL USA

[15] Virginia Commonwealth Univ, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Richmond, VA USA

[16] Diabet & Glandular Dis Clin, San Antonio, TX USA

[17] Adobe Clin Res, Tucson, AZ USA

[18] Fdn Invest, San Juan, PR USA

[19] Cumberland Res Assoc, Cumberland, MD USA

[20] Gastro One, Germantown, TN USA

[21] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA

[22] Excel Med Clin Trials, Boca Raton, FL USA

[23] Southern Therapy & Adv Res, Madison, NJ USA

[24] Ruane Clinical Res Grp Inc, Los Angeles, CA USA

[25] Progress Med Res, Port Orange, FL USA

[26] Alliance Clin Res, Alliance, OH USA

[27] South Texas Res Inst, Edinburg, TX USA

[28] Mercy Med Ctr, Baltimore, MD USA

[29] Univ Maryland, Sch Med, Baltimore, MD USA

[30] Ngm Biopharmaceut, San Francisco, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：5A / 6A

页数：2

共 50 条

[21] A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results
Idowu, Modupe
Otieno, Lucas
Dumitriu, Bogdan
Lobo, Clarisse L. C.
Thein, Swee Lay
Andemariam, Biree
Nnodu, Obiageli E.
Inati, Adlette
Glaros, Alexander K.
Olalla Saad, Sara Teresinha
Bartolucci, Pablo
Colombatti, Raffaella
Taher, Ali T.
Abboud, Miguel R.
Oluyadi, Abdulafeez
Iyer, Varsha
Yin, Ophelia
Morris, Susan
Yates, Amber M.
Shao, Hui
Patil, Spurthi
Urbstonaitis, Rolandas
Zaidi, Ahmar U.
Smith, Wally R.
BLOOD, 2023, 142
[22] Responder Rates to Atogepant in Patients With Episodic Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
Dodick, David W.
Ailani, Jessica
Goadsby, Peter J.
Trugman, Joel M.
Finnegan, Michelle
Lakkis, Hassan
Li, Ye
Szegedi, Armin
CEPHALALGIA, 2019, 39 : 183 - 184
[23] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
Dodick, D. W.
Ailani, J.
Goadsby, P. J.
Trugman, J. M.
Finnegan, M.
Lakkis, H.
Li, Y.
Szegedi, A.
HEADACHE, 2019, 59 : 79 - 80
[24] Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
Hirschfield, Gideon M.
Chazouilleres, Olivier
Drenth, Joost P.
Thorburn, Douglas
Harrison, Stephen A.
Landis, Charles S.
Mayo, Marlyn J.
Muir, Andrew J.
Trotter, James F.
Leeming, Diana J.
Karsdal, Morten A.
Jaros, Mark J.
Ling, Lei
Kim, Kathline H.
Rossi, Stephen J.
Somaratne, Ransi M.
DePaoli, Alex M.
Beuers, Ulrich
JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 483 - 493
[25] A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Pedrosa, Marcos
Seyedkazemi, Star
Francque, Sven
Sanyal, Arun
Rinella, Mary
Charlton, Michael
Loomba, Rohit
Ratziu, Vlad
Kochuparampil, Jossy
Fischer, Laurent
Vaidyanathan, Sujata
Anstee, Quentin M.
CONTEMPORARY CLINICAL TRIALS, 2020, 88
[26] A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
Ratziu, Vlad
Sheikh, Muhammad Y.
Sanyal, Arun J.
Lim, Joseph K.
Conjeevaram, Hari
Chalasani, Naga
Abdelmalek, Manal
Bakken, Anezi
Renou, Christophe
Palmer, Melissa
Levine, Robert A.
Bhandari, B. Raj
Cornpropst, Melanie
Liang, Wei
King, Benjamin
Mondou, Elsa
Rousseau, Franck S.
McHutchison, John
Chojkier, Mario
HEPATOLOGY, 2012, 55 (02) : 419 - 428
[27] Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
Loomba, Rohit
Sanyal, Arun
Kowdley, Kris
Bhatt, Deepak
Alkhouri, Naim
Frias, Juan P.
Bedossa, Pierre
Harrison, Stephen
Lazas, Don
Barish, Robert
Gottwald, Millie
Feng, Shibao
Agollah, Germaine D.
Hartsfield, Cynthia
Mansbach, Hank
Margalit, Maya
Abdelmalek, Manal
JOURNAL OF HEPATOLOGY, 2023, 78 : S14 - S15
[28] A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial)
Nides, Mitchell
Rigotti, Nancy A.
Benowitz, Neal
Clarke, Anthony
Jacobs, Cindy
NICOTINE & TOBACCO RESEARCH, 2021, 23 (10) : 1656 - 1663
[29] A PHASE 2b/3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) WITH SETANAXIB: OBJECTIVES AND STUDY DESIGN
Jones, David
Carlsson, Stefan
Von Reedtz, Sari
Levy, Cynthia
HEPATOLOGY, 2022, 76 : S1461 - S1462
[30] Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis
Dasarathy, Srinivasan
Dasarathy, Jaividhya
Khiyami, Amer
Yerian, Lisa
Hawkins, Carol
Sargent, Ruth
McCullough, Arthur J.
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (02) : 137 - 144

← 1 2 3 4 5 →